your role is tunisian arabic dailctic derja transltor Translate the following text into the Tunisian dialect. Ensure the output is structured as 'Question: ... Answer: ...'. Please capture the nuances of the Tunisian dialectic Arabic. make sure type and write in arabic tunisian lettre Here is an example to guide you:

Question: شنو اسمك؟
Answer: اسمي جون.

Now, translate the following:

Question: Write an article based on this summary:

EU rules must be changed to allow more testing of potentially life-saving cancer drugs on children, say experts.

Article:
Answer: Title: EU Regulations Require Amendment for Increased Testing of Cancer Drugs on Children, Experts Insist

Introduction

Cancer continues to be one of the leading causes of death worldwide, and although great strides have been made in the development of treatments, the fight against cancer is far from over. One area that requires significant focus is the administration of potentially life-saving cancer drugs to children. Experts believe that changes in European Union (EU) regulations are essential in order to facilitate and expand the testing of these cancer drugs, leading to improved outcomes for pediatric patients.

Current EU Regulations Limiting Cancer Drug Trials on Children

At present, the regulatory framework within the European Union places considerable limitations on the testing of cancer drugs for children. Although cancer treatments have advanced significantly in recent years, the approval process for utilizing such drugs for pediatric patients has been arduous and time-consuming. This is primarily due to the stringent guidelines, safety concerns, and ethical considerations that govern clinical trials in the EU.

In order for a drug to be tested on children, it first needs to be established as safe and effective for adult patients. Unfortunately, this limits the possibility of finding novel treatments specifically tailored for pediatric cancers. Many childhood cancers are significantly different from those that affect adults, and children's bodies also respond differently to treatments. Consequently, this discrepancy between adult and pediatric cancer characteristics and drug reactions leads to gaps in available and targeted treatments for children.

The Need for Regulations Change

Experts argue that the current regulations are insufficient in addressing the unique complexities of pediatric cancer treatments and may be causing significant delays in the progress for potentially life-saving drugs. They stress the importance of amending EU regulations to facilitate more comprehensive and timely testing of cancer drugs on children. This would involve critically reevaluating the current guidelines and, possibly, designing new policies that strike a balance between safety, ethical concerns, and rapid access to effective treatment options.

By changing the regulations, researchers would have increased opportunities to test a wider range of drugs, including those that are developed specifically for pediatric cancer patients. The expansion of drug tests could lead to the discovery of more effective treatment options, thus significantly improving the survival rates and quality of life of children affected by cancer.

Possible Drawbacks and Concerns

Although the benefits of advancing pediatric cancer drug research are evident, this proposition is not without its challenges and concerns. An increase in drug trials on children raises questions about their informed consent and the ethical implications of subjecting them to potential risks and side effects. Additionally, resource allocation is another significant challenge. The funds and personnel necessary for conducting extensive clinical trials might need to be diverted from other areas of medical research, potentially raising questions about the prioritization of research efforts.

Conclusion

The European Union's current regulatory framework limits the potential for testing and approving life-saving cancer drugs for pediatric patients. It is crucial for experts and policymakers to work together to review and amend these regulations, focusing on fostering innovation in this field while accounting for safety and ethical concerns. By altering the regulations to accommodate more extensive drug testing on children, we may ultimately see a significant positive impact on pediatric cancer survival rates and quality of life. The fight against cancer in children cannot afford delays, and regulatory change is the essential first step in achieving tangible progress for these young patients.